GWM
SRNE

Geneos Wealth Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Geneos Wealth Management’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-17,850
Closed -$146K – 3176
2021
Q1 		$146K Hold
17,850
– – ﹤0.01% 1117
2020
Q4 		$147K Buy
17,850
+9,710
+119% +$78K 0.01% 964
2020
Q3 		$78K Buy
8,140
+5,000
+159% +$45.8K ﹤0.01% 1056
2020
Q2 		$18K Buy
+3,140
New +$12K ﹤0.01% 1678

Other funds holding SRNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Geneos Wealth Management's SRNE Position: Q2 2021 in Review

Geneos Wealth Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2021, closing a stake of 17,850 shares — an estimated $146K sold.

Geneos Wealth Management first reported a position in SRNE in Q2 2020 and held it in 4 quarters. The position peaked at $147K in Q4 2020. 212 funds tracked by Wall St. Rank hold SRNE as of Q2 2021.

  • Geneos Wealth Management reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
  • Geneos Wealth Management sold 17,850 Sorrento Therapeutics, Inc. shares in Q2 2021, an estimated $146K.
  • Geneos Wealth Management first reported a position in Sorrento Therapeutics, Inc. in Q2 2020 and held it in 4 quarters.
  • Geneos Wealth Management's Sorrento Therapeutics, Inc. position peaked at $147K in Q4 2020.
  • 212 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2021.

Based on Geneos Wealth Management's 13F filing for Q2 2021, filed 8 Jul 2021.